MedTrace Logo

Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)

NCT01863199 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-10-04

No results posted yet for this study

Summary

A study to use in home technology to reduce the burden of in office visits and injections.

Conditions

  • Neovascular Age Related Macular Degeneration

Interventions

DRUG

Lucentis (Treat and extend)

Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.

DRUG

Lucentis every 4 weeks

Lucentis 0.5mg administered intravitreally every four weeks for 12 months

DRUG

Lucentis every 12 weeks

Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Retinal Consultants of Arizona

    lead OTHER

Principal Investigators

  • Pravin U Dugel, MD · Retinal Consultants of Arizona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-11-30
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01863199 on ClinicalTrials.gov